The impact of molecular testing on the surgical management of patients with thyroid nodules

Annals of Surgical Oncology

Volumn 21, Issue 6, 2014, Pages 1862-1869

  Aragon Han, Patricia ^a   Olson, Matthew T ^a   Fazeli, Roghayeh ^a   Prescott, Jason D ^a   Pai, Sara I ^a   Schneider, Eric B ^a   Tufano, Ralph P ^a   Zeiger, Martha A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MOLECULAR MARKER; PROTEIN PATCHED; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PROTEIN RET; RET PROTEIN, HUMAN;

ADULT; ALGORITHM; ARTICLE; ATYPIA OF UNDETERMINED SIGNIFICANCE; BRAF GENE; BRAF MUTATION ANALYSIS; CANCER SURGERY; CENTRAL LYMPH NODE DISSECTION; CONSENSUS; CONSULTATION; DIAGNOSTIC TEST ACCURACY STUDY; DNA BASED SOMATIC MUTATION PANEL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HEMITHYROIDECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MOLECULAR DIAGNOSIS; ONCOGENE; ONCOGENE N RAS; ONCOGENE RET; PAPILLARY THYROID CANCER; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PTC GENE; RNA BASED GENE EXPRESSION CLASSIFIER; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; SURGEON; SUSPICIOUS FOR MALIGNANCY; TERTIARY CARE CENTER; THYROID CARCINOMA; THYROID NODULE; THYROID SURGERY; THYROIDECTOMY; DECISION SUPPORT SYSTEM; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; RETROSPECTIVE STUDY; THYROID GLAND;

ADULT; ALGORITHMS; BIOPSY, FINE-NEEDLE; DECISION SUPPORT TECHNIQUES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID NODULE;

EID: 84902211609     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3508-x     Document Type: Article

References (27)

1. Brander A, Viikinkoski P, Tuuhea J, Voutilainen L, Kivisaari L. Clinical versus ultrasound examination of the thyroid gland in common clinical practice. J Clin Ultrasound. 1992;20(1):37-42.
2. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111(6):508-16.
3. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
4. Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA Cancer J Clin. 2009;59(2):99-110.
5. Olson MT, Clark DP, Erozan YS, Ali SZ. Spectrum of risk of malignancy in subcategories of 'atypia of undetermined significance'. Acta Cytol. 2011;55(6):518-25.
6. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-7.
7. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8):705-15.
8. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96(7):2016-26.
9. Tetzlaff MT, LiVolsi V, Baloch ZW. Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland. Adv Anat Pathol. 2006;13(5):228-37.
10. Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta cytologica. 2011;55(6):570-5.
11. Canadas-Garre M, Becerra-Massare P, Lopez de la Torre-Casares M, Villar-del Moral J, Céspedes-Mas S, Vílchez-Joya R, et al. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. Ann Surg. 2012;255(5):986-992.
12. Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009;19(8):837-42.
13. Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 2010;95(8):3693-700.
14. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94(6):2092-8.
15. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95(3):1365-9.
16. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol B. 2006;15(3):136-43.
17. Ward LS, Kloos RT. Molecular markers in the diagnosis of thyroid nodules. Arquivos Brasileiros Endocrinol Metab. 2013;57(2):89-97.
18. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625-7.
19. Kleiman DA, Sporn MJ, Beninato T, Crowley MJ, Nguyen A, Uccelli A, et al. Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. Cancer. 2013;119(8):1495-502.
20. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group EGW. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v214-9.
21. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group EGW. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):110-119.
22. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-42.
23. Olson MT, Boonyaarunnate T, Aragon Han P, Umbricht CB, Ali SZ, Zeiger MA. A tertiary center's experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab. 2013;98(4):1450-7.
24. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159-65.
25. Fisher RA. The logic of inductive inference. J R Stat Soc. 1935;98(1):39-82.
26. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309(6947):102.
27. Guyatt GH, Sackett D, Haynes RB. Evaluating diagnostic tests. In: Haynes RB, Sackett DL, Guyatt GH, Tugwell P, eds. Clinical epidemiology: how to do clinical practice research. 3rd edn. Philadelphia: Lippincott Williams & Wilkins; 2006:273-322.